City File: Zantac
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.PRODUCING a blockbuster drug takes a lot of know-how, a good deal of luck and a good sales force. Since that combination is hard to come by more than once in a while, pharmaceutical companies are unable to regularly churn out best-sellers. Look at Glaxo. It has spent hundreds of millions of pounds searching for a successor to Zantac, which it hopes will be a similar tonic to profits.
But so far it has not found one, which has caused many supporters to shake their heads pessimistically. But at the same time, Glaxo is gradually building up a healthy stable of second-line drugs which, added together, are not a bad substitute for the real thing.
Last week, the US authorities approved its latest migraine treatment, Sumatriptan. The shares immediately rose 27p to 774p. The drug is better than its rivals and therefore highly priced. It is one of a new generation of Glaxo drugs, four of which could account for a quarter of worldwide sales within five years.
In the long run, a pharmaceutical company reliant on a portfolio of drugs must be a more attractive investment than one searching for an elusive world-beater.
(Graph omitted)
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments